Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://www.rdinvesting.com/ and get exclusive access to our numerous stock reports and market updates.
Accretive Health, Inc. (NYSE: AH) shares declined 4.02 percent to close at $9.54 a share Tuesday. The stock traded between $9.28 and $9.62 on volume of 430,223 shares traded. Analysts at Oppenheimer have recently downgraded the company’s rating to "perform" from "outperform". Shares of Accretive Health have fallen approximately 17.0 percent year-to-date.
Find out more about Accretive Health including full access to the free equity report at:
Brady Corp. (NYSE: BRC) shares declined 2.52 percent to close at $34.02 a share Tuesday. The stock traded between $34.01 and $34.63 on volume of 130,357 shares traded. Analysts at Robert W. Baird have recently upgraded the company’s rating to "outperform" from "neutral". Shares of Brady have gained approximately 2.0 percent year-to-date.
Find out more about Brady including full access to the free equity report at:
Control4 Corp. (NASDAQ: CTRL) shares increased 2.60 percent to close at $22.53 a share Tuesday. The stock traded between $21.51 and $22.73 on volume of 122,557 shares traded. Analysts at Needham have recently initiated coverage on the company with a "buy" rating. Shares of Control4 have gained approximately 12.0 percent year-to-date.
Find out more about Control4 including full access to the free equity report at:
Cimarex Energy Co. (NYSE: XEC) shares increased 0.68 percent to close at $82.87 a share Tuesday. The stock traded between $81.64 and $85.04 on volume of 1.60 million shares traded. Analysts at FBR Capital have recently upgraded the company’s rating to "outperform" from "market perform". Shares of Cimarex Energy have gained approximately 43.0 percent year-to-date.
Find out more about Cimarex Energy including full access to the free equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Research Driven Investing
Leave a comment...